Cargando…

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

BACKGROUND: The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib. Chromatin-modifying agents may offer a novel therapeutic approach by sensitizing tumor cells to TKIs. METHODS: The NSCLC cell lines H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greve, Gabriele, Schiffmann, Insa, Pfeifer, Dietmar, Pantic, Milena, Schüler, Julia, Lübbert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682236/ https://www.ncbi.nlm.nih.gov/pubmed/26675484 http://dx.doi.org/10.1186/s12885-015-1967-5

Ejemplares similares

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

Design and synthesis of diazine-based panobinostat analogues for HDAC8 inhibition
por: Balasubramaniam, Sivaraman, et al.
Publicado: (2020)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
por: Xiaobo, Cao, et al.
Publicado: (2016)

HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients’ T-cells
por: Schnell, Annika P., et al.
Publicado: (2022)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

In vitro and in vivo anti−Toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis
por: Zhang, Yu, et al.
Publicado: (2022)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
por: Singh, Avineesh, et al.
Publicado: (2016)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy
por: Dai, Bingbing, et al.
Publicado: (2015)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
por: Di Fazio, Pietro, et al.
Publicado: (2010)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
por: Xu, Naiqing, et al.
Publicado: (2015)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
por: Xu, Naiqing, et al.
Publicado: (2018)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
por: Chou, Chia-Wei, et al.
Publicado: (2011)

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non–Small Cell Lung Cancer Cells()
por: Saygideğer-Kont, Yasemin, et al.
Publicado: (2016)

Single-Cell Sequencing Identifies Master Regulators Affected by Panobinostat in Neuroblastoma Cells
por: Milazzo, Giorgio, et al.
Publicado: (2022)

Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic
por: Weiss, Glen J., et al.
Publicado: (2014)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression()
por: Groselj, Blaz, et al.
Publicado: (2013)

Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma
por: Wirries, André, et al.
Publicado: (2018)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines
por: Pacheco, Mariana Brütt, et al.
Publicado: (2021)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Wildtype epidermal growth factor receptor (Egfr) is not required for daily locomotor or masking behavior in mice
por: Roberts, Reade B, et al.
Publicado: (2006)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Panobinostat for the treatment of multiple myeloma: the evidence to date
por: Bailey, Hanna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c57on76d581gjhqlh8ldp6gmq0